Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus vs Cyclosporine in Kidney Transplant from Older Donors
NCT00195273Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2004
- Primary completion
- Jul 2008
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of nab-sirolimus in kidney transplant rejection (2 arms), sponsored by Pfizer. Primary endpoint: Mean Creatinine Clearance Rate at 12 months. Started Nov 2004; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00195273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195273.